EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische StudieOpen Access · CC BY 4.0

Ruxolitinib for Emergency Treatment of COVID‐19–Associated Cytokine Storm: Findings From an Expanded Access Study

Jeffrey Weinstein iD, Nikhil Jagan, Shawnta Lorthridge-Jackson, J E Hamer-Maansson, Peg Squier

The Clinical Respiratory Journal · 2025

DOI: 10.1111/crj.70050 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift The Clinical Respiratory Journal, 2025. Verfasst von Jeffrey Weinstein und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Quality and Infection Prevention and Control, Kettering Health Network, Dayton, Ohio, USA. Hauptthemen laut MEDLINE: Pyrazoles, Cytokine Release Syndrome, COVID-19 Drug Treatment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Incyte Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This expanded access program (EAP) provided ruxolitinib (oral, selective Janus kinase [JAK]1/JAK2 inhibitor) for emergency treatment of COVID‐19–associated cytokine storm in patients eligible for hospitalization (NCT04355793).

Methods

Patients received ruxolitinib 5 mg twice daily (preferred regimen when tolerated) or once daily for ≤ 14 days, or until determination of no clinical benefit was made. Outcomes were clinical status, physician‐assessed clinical benefit, and serious adverse event (SAE) incidence.

Results

Of 312 patients, 45.5% achieved ≥ 1‐point clinical status improvement. Physician‐assessed clinical benefit was reported in 42.6% of evaluable patients. SAEs occurred in 42.9%, with 2.6% experiencing an SAE suspected to be ruxolitinib related.

Conclusions

Overall, some hospitalized patients with COVID‐19–associated cytokine storm who received ruxolitinib experienced clinical status improvement; ruxolitinib was well tolerated. Trial Registration ClinicalTrials.gov identifier: NCT04355793

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesCytokine Release SyndromeCOVID-19 Drug TreatmentHumansNitrilesPyrimidinesMaleFemaleCOVID-19Middle AgedAgedTreatment OutcomeSARS-CoV-2AdultJanus Kinase Inhibitors

Stichwörter der Autor:innen

COVID‐19Janus kinase inhibitorsacute respiratory distress syndromecytokine release syndromeexpanded accesshospitalization

Substanzen

ruxolitinibNitrilesPyrazolesPyrimidinesJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Quality and Infection Prevention and Control, Kettering Health Network, Dayton, Ohio, USA.
  • Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska, USA.
  • Medical Affairs, Incyte Corporation, Wilmington, Delaware, USA.

ORCID-Profile: Jeffrey Weinstein

Förderung

  • Incyte Corporation

Zitieren

APA

Weinstein, J., Jagan, N., Lorthridge-Jackson, S., Hamer-Maansson, J. E., & Squier, P. (2025). Ruxolitinib for Emergency Treatment of COVID‐19–Associated Cytokine Storm: Findings From an Expanded Access Study. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.70050

Vancouver

Weinstein J, Jagan N, Lorthridge-Jackson S, Hamer-Maansson JE, Squier P. Ruxolitinib for Emergency Treatment of COVID‐19–Associated Cytokine Storm: Findings From an Expanded Access Study. The Clinical Respiratory Journal. 2025. doi:10.1111/crj.70050

BibTeX
@article{Weinstein2025,
  author = {Weinstein, Jeffrey and Jagan, Nikhil and Lorthridge-Jackson, Shawnta and Hamer-Maansson, J E and Squier, Peg},
  title = {Ruxolitinib for Emergency Treatment of COVID‐19–Associated Cytokine Storm: Findings From an Expanded Access Study},
  journal = {The Clinical Respiratory Journal},
  year = {2025},
  doi = {10.1111/crj.70050}
}
Kostenlos starten →